International law firm Brown Rudnick served as lead intellectual property counsel to Eliem Therapeutics for its August 10, 2021, initial public offering. Eliem focuses on potential treatments for neural excitability disorders like chronic pain, epilepsy, and anxiety. The company raised $80 million, selling 6.4 million shares priced at $12.50 each. The stock opened at $16.50 and rose to $19 before closing at $15.90, up 27% from the offer price. SVB Leerink, Evercore ISI, Stifel, and Guggenheim Securities were joint bookrunners on the deal. Eliem’s stock trades on NASDAQ, the ticker symbol is ELYM.

The Brown Rudnick deal team included Adam Schoen and Mark Nickas. Brown Rudnick’s Global Life Sciences Group consists of a dedicated team of lawyers and includes former biotech and healthcare executives and scientists who have a deep understanding of the life sciences industry.

Read more about Brown Rudnick’s Life Sciences Group here.